Form 4: Contineum Therapeutics Officer Acquires Stock Options
SEC Form 4
John Stephen Healy, General Counsel and Corporate Secretary of Contineum Therapeutics, acquired stock options for 63,589 shares on January 31, 2025.
Summary
- On January 31, 2025, John Stephen Healy, General Counsel and Corporate Secretary of Contineum Therapeutics, acquired options to purchase 63,589 shares of Class A Common Stock.
- The options were granted under the Issuer's 2024 Equity Incentive Plan with an exercise price of $9.79.
- 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, and does not contain information that would significantly impact sentiment positively or negatively.
Positives
- The grant of stock options aligns the interests of the General Counsel and Corporate Secretary with those of the shareholders.
- The vesting schedule incentivizes continued service and contribution to the company's success.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The stock option grant could have a minor positive impact on shareholder sentiment by aligning management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of transaction: John Stephen Healy acquired stock options. |
| 01/31/2025 | Date of signature. |
| 01/01/2026 | 25% of the option shares vest. |
| 01/30/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.